Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-132 (Divozilimab) vs Teriflunomide and Placebo in Relapsing-Remitting Multiple Sclerosis
NCT04056897Phase 2Completed
- Sponsor
- BIOCAD
- Start
- Jun 2019
- Primary completion
- Jul 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Divozilimab in relapsing-remitting multiple sclerosis (RRMS), sponsored by BIOCAD. Started Jun 2019; status: completed.
02
Drugs
Divozilimab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT04056897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04056897.